Harris Andrew C, Pentel Paul R, LeSage Mark G
Minneapolis Medical Research Foundation, Minneapolis, MN 55404, USA.
Psychopharmacology (Berl). 2009 Sep;205(4):599-611. doi: 10.1007/s00213-009-1567-7. Epub 2009 May 28.
The ability of tobacco harm reduction strategies to produce significant reductions in toxin exposure is limited by compensatory increases in smoking behavior. Characterizing factors contributing to the marked individual variability in compensation may be useful for understanding this phenomenon and assessing the feasibility of harm reduction interventions.
The objective of the study was to use an animal model of human compensatory smoking that involves a decrease in unit dose supporting nicotine self-administration (NSA) to examine potential contributors to individual differences in compensation.
Rats were trained for NSA during daily 23-h sessions at a unit dose of 0.06 mg/kg/inf until responding was stable. The unit dose was then reduced to 0.03 mg/kg/inf for at least 10 sessions. Following reacquisition of NSA at the training dose and extinction, single-dose nicotine pharmacokinetic parameters were determined.
Decreases in nicotine intake following dose reduction were proportionally less than the decrease in unit dose, indicating partial compensation. Compensatory increases in infusion rates were observed across the course of the 23-h sessions. The magnitude of compensation differed considerably between rats. Rats exhibiting the highest baseline infusion rates exhibited the lowest levels of compensation. Nicotine pharmacokinetic parameters were not significantly correlated with compensation. Infusion rates immediately returned to pre-reduction levels when baseline conditions were restored.
These findings provide initial insights into correlates of individual differences in compensation following a reduction in nicotine unit dose. The present assay may be useful for characterizing mechanisms and potential consequences of the marked individual differences in compensatory smoking observed in humans.
烟草危害降低策略在显著减少毒素暴露方面的能力受到吸烟行为代偿性增加的限制。确定导致代偿性显著个体差异的因素,可能有助于理解这一现象,并评估降低危害干预措施的可行性。
本研究的目的是使用一种人类代偿性吸烟的动物模型,该模型涉及支持尼古丁自我给药(NSA)的单位剂量降低,以研究代偿性个体差异的潜在影响因素。
大鼠在每天23小时的实验中接受NSA训练,单位剂量为0.06mg/kg/次,直至反应稳定。然后将单位剂量降至0.03mg/kg/次,持续至少10次实验。在以训练剂量重新获得NSA并消退后,测定单剂量尼古丁的药代动力学参数。
剂量降低后尼古丁摄入量的减少比例小于单位剂量的减少比例,表明存在部分代偿。在23小时的实验过程中观察到输注速率的代偿性增加。大鼠之间的代偿程度差异很大。基线输注速率最高的大鼠代偿水平最低。尼古丁药代动力学参数与代偿无显著相关性。当恢复基线条件时,输注速率立即恢复到降低前的水平。
这些发现为尼古丁单位剂量降低后代偿性个体差异的相关因素提供了初步见解。本试验可能有助于表征在人类中观察到的代偿性吸烟显著个体差异的机制和潜在后果。